CFRXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CFRXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. ContraFect's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0. ContraFect's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2024-06-08), ContraFect's share price is $0.0151. ContraFect's Median PS Value is $0.00. Therefore, ContraFect's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for ContraFect's Median PS Value or its related term are showing as below:
The historical data trend for ContraFect's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContraFect Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
ContraFect Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, ContraFect's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ContraFect's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where ContraFect's Price-to-Median-PS-Value falls into.
ContraFect's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
ContraFect's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContraFect (OTCPK:CFRXQ) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
ContraFect's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 0.0151 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of ContraFect's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Lishan Aklog | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171 |
Michael Messinger | officer: VP Finance | 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534 |
Cary Sucoff | director | 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904 |
David N. Low | director | EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111 |
Sol J Barer | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Lisa Ricciardi | director | C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
Joshua B Muntner | officer: SVP Business Development | 30 FIFTH AVENUE, 12F, NEW YORK NY 10011 |
Shanghai Fosun Pharmaceutical (group) Co., Ltd. | 10 percent owner | BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233 |
Fosun Industrial Co., Ltd | 10 percent owner | FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000 |
Cara M Cassino | officer: Chief Medical Officer | 757 STONY POINT ROAD, BENSON VT 05743 |
Natalie Bogdanos | officer: General Counsel | 207-23 DARREN DRIVE, BAYSIDE NY 11360 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Michael J. Otto | director | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By sperokesalga sperokesalga • 04-20-2023
By sperokesalga sperokesalga • 02-28-2023
By PurpleRose PurpleRose • 08-15-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By sperokesalga sperokesalga • 06-20-2023
By GuruFocusNews GuruFocusNews • 07-04-2022
By Value_Insider Value_Insider • 12-19-2022
By PRNewswire PRNewswire • 02-27-2023
By GuruFocusNews GuruFocusNews • 06-19-2022
By sperokesalga sperokesalga • 05-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.